Back In Biotech, Waksal's Kadmon Emerges From Stealth Mode To Focus on Hep C
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.